Skip to product information
1 of 1

SANOFI SpA

Maalox plus 30 chewable tablets

Maalox plus 30 chewable tablets

Regular price €11,90 EUR
Regular price Sale price €11,90 EUR
Sale Sold out
Tax included. Shipping calculated at checkout.
Logo Farmaci da banco

PRODUCT NET WEIGHT

EAN

020702080

MINSAN

020702080

View full details

Maalox Plus 30 Chewable Tablets is a medicine indicated for the symptomatic treatment of heartburn or stomach pain, due to hyperacidity and gastroesophageal reflux.

Maalox Plus reduces the amount of acid in the stomach and excess intestinal gas. Maalox Plus is also indicated for the treatment of peptic ulcers .

 

ACTIVE INGREDIENTS

Active ingredients in Maalox plus 30 chewable tablets - What is the active ingredient in Maalox plus 30 chewable tablets?

100 ml of suspension contains the active substances: magnesium hydroxide 3.65 g, aluminium hydroxide 3.25 g, dimethicone 0.50 g. Excipient(s) with known effect: methyl parahydroxybenzoate, propyl parahydroxybenzoate, ethanol, invert sugar, sucrose, sulphur dioxide (E 220), sorbitol (E420) 4.48 g/ 100 ml (see section 4.4). For the full list of excipients, see section 6.1. One tablet contains the active substances: magnesium hydroxide 200 mg, aluminium oxide, hydrate 200 mg, dimethicone 25 mg. Excipient(s) with known effect: glucose, sucrose, sorbitol (E420) 45 mg per tablet (see section 4.4). For the full list of excipients, see section 6.1.

 

EXCIPIENTS

Composition of Maalox plus 30 chewable tablets - What does Maalox plus 30 chewable tablets contain?

Maalox Plus 3.65% + 3.25% + 0.5% oral suspension: methylcellulose, methyl parahydroxybenzoate, propyl parahydroxybenzoate, carmellose, hydroxypropylcellulose, citric acid, sodium saccharin, sorbitol (E420) non-crystallising liquid, lemon flavouring (containing ethanol), Swiss cream flavouring (containing ethanol, invert sugar, sucrose, sulphur dioxide (E 220)), purified water. Maalox Plus 200 mg +200 mg + 25 mg chewable tablets: corn starch, citric acid, pregelatinized starch, glucose, mannitol, sucrose, sorbitol (E420), non-crystallizing liquid sorbitol, talc, magnesium stearate, sodium saccharin, lemon flavouring, Swiss cream flavouring, E 172.

 

DIRECTIONS

Therapeutic indications Maalox plus 30 chewable tablets - Why is Maalox plus 30 chewable tablets used? What is it used for?

Symptomatic treatment of hyperacidity (including burning and pain) including in cases of esophagitis, and of hyperacidity when accompanied by dyspepsia. Symptomatic treatment of gastrointestinal bloating when accompanied by hyperacidity.

 

CONTRAINDICATIONS SIDE EFFECTS

Contraindications Maalox plus 30 chewable tablets - When should Maalox plus 30 chewable tablets not be used?

Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1; patients with porphyria; severe forms of renal insufficiency (creatinine clearance less than 30 mL/min); generally contraindicated in pediatric age; state of cachexia.

 

DOSAGE

Quantity and method of taking Maalox plus 30 chewable tablets - How to take Maalox plus 30 chewable tablets?

Maalox Plus 3.65% + 3.25% + 0.5% oral suspension. Dosage: do not exceed the maximum doses indicated unless prescribed by a doctor. Ingest 2-4 teaspoons (10-20 ml) 4 times a day, 20-60 minutes after meals and before going to bed. Method of administration: shake well before use. It can be diluted in water or milk. Maalox Plus 200 mg + 200 mg + 25 mg chewable tablets. Dosage: do not exceed the maximum doses indicated unless prescribed by a doctor. 2-4 tablets 4 times a day, chewed or sucked well, 20-60 minutes after meals and before going to bed. Method of administration: the tablets must be chewed or sucked well. Their intake can be followed by ingestion of water or milk. Paediatric population: administration of the medicine in paediatric age is not recommended.

 

CONSERVATION

Storage Maalox plus 30 chewable tablets - How to store Maalox plus 30 chewable tablets?

Oral suspension: Do not store below 4 degrees C. Bottle: Keep the bottle tightly closed. Chewable tablets: Store below 25 degrees C.

 

WARNINGS

Warnings Maalox plus 30 chewable tablets - About Maalox plus 30 chewable tablets it is important to know that:

Aluminium hydroxide may cause constipation and an overdose of magnesium salts may cause intestinal hypermotility; high doses of this medicine may cause or worsen intestinal obstruction and ileus in patients at higher risk, such as those with renal impairment, with underlying constipation, with impaired intestinal motility, in children (0 to 24 months), or in the elderly. Aluminium hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients on low-phosphorus diets or in children (0 to 24 months), may lead to phosphate excretion (due to an aluminium-phosphate bond) accompanied by increased bone resorption and hypercalciuria with risk of osteomalacia. It is advisable to consult a doctor in case of long-term use or in patients at risk of hypophosphatemia. In patients with renal impairment, plasma levels of aluminum and magnesium tend to increase, causing hyperaluminemia and hypermagnesemia, respectively. In these patients, long-term exposure to high doses of aluminum and magnesium salts may lead to encephalopathy, dementia, microcytic anemia or worsening of dialysis-induced osteomalacia. In the presence of mild and moderate forms of renal insufficiency, it is advisable to take the product under medical supervision. Prolonged use of antacids in patients with mild and moderate forms of renal insufficiency should be avoided. The administration of this medicinal product is contraindicated in subjects suffering from severe forms of renal insufficiency (see section 4.3). Aluminum hydroxide may not be safe in patients with porphyria undergoing haemodialysis (see section 4.3). Maalox Plus, due to its composition, does not tend to modify bowel habits. However, in some particularly sensitive subjects and for high doses, an acceleration of intestinal transit may occur. Maalox Plus 3.65% + 3.25% + 0.5% oral suspension contains parahydroxybenzoates: may cause allergic reactions (possibly delayed); 448 mg of sorbitol (E420) in 10 ml (2 teaspoons). Patients with hereditary fructose intolerance should not be given this medicine; ethanol: this medicine contains 9.5 mg of ethanol in 10 ml (2 teaspoons). 10 ml of this medicine is equivalent to 0.2 ml of beer or 0.1 ml of wine. The small amount of alcohol in this medicine will not produce any relevant effects; sucrose and invert sugar: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine; sulphur dioxide (E 220): may rarely cause severe hypersensitivity reactions and bronchospasm; less than 1 mmol sodium (23 mg) per dose, i.e. essentially "sodium-free". Maalox Plus 200 mg + 200 mg + 25 mg chewable tablets contain: 45 mg disorbitol, per tablet. The concomitant administration of medicinal products containing sorbitol (or fructose) and the daily intake of sorbitol (or fructose) with the diet should be taken into account. The sorbitol content in oral medicinal products may alter the bioavailability of other concomitant oral medicinal products. Patients with hereditary fructose intolerance should not be given this medicine. Approximately 500 mg glucose, per tablet: to be taken into account in patients with diabetes mellitus, if more than 10 tablets per day are taken; patients with rare problems of glucose-galactose malabsorption should not take this medicine. Sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Less than 1 mmol sodium (23 mg) per tablet, i.e. essentially "sodium-free". Paediatric population: In young children, the use of magnesium hydroxide may lead to hypermagnesaemia, particularly if they have renal impairment or dehydration.

 

INTERACTIONS

Maalox plus 30 chewable tablets interactions - Which medicines or foods can modify the effect of Maalox plus 30 chewable tablets?'

Since Al and Mg salts reduce the gastrointestinal absorption of tetracyclines, it is recommended to avoid taking Maalox Plus during oral tetracycline therapy. The use of aluminum-containing antacids may reduce the absorption of drugs, particularly H2-antagonists, atenolol, bisphosphonates, cefdinir, cefpodoxime, chloroquine, tetracyclines, dasatinib monohydrate, diflunisal, digoxin, dexamethasone, eltrombopag olamine, elvitegravir, ethambutol, fluoroquinolones, glucocorticoids, indomethacin, iron salts, isoniazid, ketoconazole, levothyroxine, lincosamides, metoprolol, nilotinib, phenothiazine neuroleptics, penicillamine, propranolol, raltegravir potassium, rilpivirine, riociguat, rosuvastatin, sodium fluoride and antiviral treatments in combination with tenofovir alafenamide fumarate/emtricitabine/ bictegravir sodium. Polystyrene sulfonate (Kayexalate): Caution is advised when the medicinal product is taken together with polystyrene sulfonate (Kayexalate) due to the potential risk of reduced efficacy of the resin in binding potassium, metabolic alkalosis in patients with renal impairment (reported with aluminium hydroxide and magnesium hydroxide), and intestinal obstruction (reported with aluminium hydroxide). Aluminium hydroxide and citrates may cause hypoalbuminaemia, especially in patients with renal impairment. The combination with integrase inhibitors (dolutegravir, raltegravir, bictegravir) and Maalox Plus should be avoided (refer to their respective SmPCs for dose recommendations). Since the use of magnesium hydroxide causes alkalinization of urine, increased excretion of salicylates has been observed when administered concomitantly. As a precaution, allow at least 2 hours (4 hours for fluoroquinolones) to elapse between taking any oral medication and Maalox Plus. Concomitant use of quinidine may increase serum quinidine levels and lead to quinidine overdose. Concomitant use of aluminum hydroxide and citrates may increase aluminum levels, particularly in patients with renal insufficiency. Alkalinization of urine following administration of magnesium hydroxide may alter the excretion of some drugs; therefore, increased excretion of salicylates has been observed.

 

SIDE EFFECTS

Like all medicines, Maalox plus 30 chewable tablets can cause side effects - What are the side effects of Maalox plus 30 chewable tablets?

The frequency of adverse reactions listed below is defined using the following conventions: common (>=1/100, <1/10); uncommon (>=1/1,000, <1/100); rare (>=1/10,000, <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Immune system disorders. Frequency not known (cannot be estimated from the available data): angioedema, anaphylactic reactions, hypersensitivity reactions, urticaria, pruritus. Gastrointestinal disorders. Uncommon: diarrhoea or constipation (see section 4.4); frequency not known: abdominal pain. Metabolism and nutrition disorders. Very rare: hypermagnesaemia, including observations after prolonged administration to patients with renal impairment; frequency not known: hypoalbuminaemia, hypophosphatemia, during prolonged use or at high doses or even at normal doses of the medicinal product in patients with low phosphorus diets or in children (0 to 24 months), which may cause increased bone resorption, hypercalciuria, osteomalacia (see section 4.4). Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

 

PREGNANCY AND BREASTFEEDING

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Maalox plus 30 chewable tablets.

There are no data on the use of Maalox Plus in pregnant women. It is not possible to establish whether or not the use of Maalox Plus during pregnancy is safe. Pregnancy: the medicine should be used only in case of need, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus or the infant. Breastfeeding: due to the limited maternal absorption when taken according to the indicated dosage regimen (see section 4.2), aluminium hydroxide and its combinations with magnesium salts are considered compatible with breastfeeding.

  • HELP CENTER

  • SHIPPING

    Shipping in Italy 24/48H
    Delivery also on Saturday and Sunday
    Free over €49.90


    Shipping in Europe 24/72H
    Free over €80


    Shipping to UK 24/72H
    Free over €150

  • SAFETY

    The security of your data matters to us!


    We are fully compliant with the European GDPR regarding Privacy and Processing of personal data.


    Payments you make on our site are 100% safe and guaranteed.

  • RETURNS

    Fast returns through do-it-yourself portal and 14 days to reconsider.


    Fast and free replacements for incorrect or non-compliant products delivered.

1 of 4

Responsibility for content
This sheet contains information that is not intended to replace a diagnosis or medical advice, as only a doctor can write any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.

Please note
The names of the products, the ingredients and the percentages indicated in the descriptions are purely indicative, they could be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting in real time to such updates, the photos and technical information of the products inserted on Dottortili.com may differ from those reported on the label or otherwise disseminated by the manufacturing companies. The only identification element is the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines all responsibility for any errors, omissions or failure to update the same. Dottortili.com does not assume responsibility for damages of any nature that may arise from access to the published information.

Data source: Farmadati Italia
Website: https://www.farmadati.it/

The Farmadati Italia Database is used by almost all pharmacies, parapharmacies, herbalists, health shops, large-scale retail trade, computerized doctors, etc. thanks to the company's historical guarantee of reliability, seriousness and professionalism on the national territory.

The Farmadati Italia Srl management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO/IEC 27001:2017 for information security management systems.